ClinicalTrials.gg
TerminatedNCT06636175Updated Oct 16, 2026

64Cu-LLP2A for Imaging Hematologic Malignancies

An Early Phase 1 interventional study of 64Cu-LLP2A and PET/CT in Multiple Myeloma, Low-Grade Lymphoma and Follicular Lymphoma, sponsored by Washington University School of Medicine. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Washington University School of Medicine · Early Phase 1, Interventional, and Diagnostic

How we know

Why this study was terminated
Loss of further funding
Updated Oct 16, 2026Now TerminatedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Multiple Myeloma by Washington University School of Medicine — 7 open to participants now, 11 under way, none of them phase 3. Multiple Myeloma · Washington University School of Medicine.

Enrollment
19th of 38
21 · median 21
Started
2025
with 3 others
Phase 1
17 of 40
4 open now
Registered
36th of 40
by date

Among the 40 studies in Multiple Myeloma by Washington University School of Medicine, this one is the 19th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 in phase 1, and was the 36th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.

03

Conditions studied

  • Multiple Myeloma
  • Low-Grade Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Small Lymphocytic Lymphoma
  • Chronic Lymphocytic Leukemia

Keywords

  • PET
  • Imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Healthy Volunteer:

  • Adult 18 years of age or older
  • Able to give .
  • Able to comprehend and willing to follow instructions for study procedures as called for by the protocol
  • Capable of lying still and supine within the PET/CT scanner for up to 75 minutes.
  • No illicit drug use or other inhaled drug use (including pharmacologic agents and illicit drugs) within the past year per self-reporting mechanisms.
  • No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions.
  • Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), (cessation of menses for more than 1 year), non-lactating, or of for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative.

Inclusion Criteria Hematological :

  • Clinical or defined MM or lymphoma including both newly diagnosed, disease:

    • Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria
    • Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia
  • Adult 18 years of age or older and able to provide informed consent
  • Capable of lying still and supine within the PET/CT scanner for up to 75 minutes.
  • No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions
  • Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative
  • Patients participating in imaging or therapeutic trials with agents are eligible to participate
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Pilot/Cohort 1B: Dosimetry 64Cu-LLP2A

    \- Will be asked to undergo 64Cu-LLP2A-PET/CT imaging at up to three separate time points for purposes of calculating human dosimetry. Imaging time points will be dependent upon day of the week injection occurs: * Tuesday or Thursday injection: 0-60 minute multiple quick body scans + 120-180 min post injection body scan * Wednesday or Friday injection: 0-60 minute multiple quick body scans + 180-240 min post injection body scan * ALL PATIENTS: 15-28 hours post injection body scan on Wednesday (for Tuesday injection), Thursday (for Wednesday injection), Friday (for Thursday injection) or Saturday (for Friday injection)

    Drug: 64Cu-LLP2A · Device: PET/CT

  • Experimental
    Cohort 2B: Quantitative 64Cu-LLP2A

    \- Will be asked to undergo dynamic PET/CT imaging centered over a known target lesion (as determined by other radiological imaging studies) beginning with 64Cu-LLP2A-PET/CT and continuing for a total of 60 minutes. An additional vertex to upper thigh body scan will be obtained between 60- and 180-minutes post injection or at the optimal imaging time point that was derived from cohort 1B.

    Drug: 64Cu-LLP2A · Device: PET/CT

Interventions

  • Drug64Cu-LLP2A

    64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)

  • DevicePET/CT

    The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.

06

What researchers measure

Primary outcomes

  1. Organ dosimetry of participants

    Confirm organ dosimetry in healthy subjects and in patients with various hematological malignancies is consistent with prior formulation of 64Cu-LLP2A (all of Cohort 1 + up to 10 cohort 2 subjects). Average organ activity concentration will be measured, and decay corrected by utilizing regions of interest (ROIs) drawn around all organ visible on 64Cu-LLP2A images. Activity organ residence times will be calculated by numerical or analytical integration of the time-activity curves. Uptake/clearance functional fits of mono- or bi-exponential functions will be performed and analytical integration, accounted for physical decay, will be performed. The calculated residence times will be used with the program OLINDA/EXM for 64Cu and using the adult human (female and male) model to calculate the individual organ radiation dose, the whole-body dose and the effective dose.

    Time frame: Through completion of PET/CT scans (estimated to be up to 2 days)

  2. Safety and tolerability of new formulation of 64Cu-LLP2A as measured by number of participants with adverse events

    Follow-up telephone call or in person visit to assess for self-reported adverse events associated with injection of 64Cu-LLP2A or PET/CT imaging. Additional chart review can be performed as needed.

    Time frame: From beginning of administration of 64Cu-LLPA2A through last phone call assessment (up to 7 days total)

Secondary outcomes

  1. Evaluate the quality of PET images with new formulation 64Cu-LLP2A as measured by overall quality of PET images

    Overall, PET image quality will be graded visually (using 4-point scale with 1 being the worst and poor quality, not acceptable for diagnostic interpretation and 4 being good image quality, similar to routine clinical studies)

    Time frame: Through completion of PET/CT scans (estimated to be up to 2 days)

  2. Evaluate the quality of PET images with new formulation 64Cu-LLP2A as measured by bone marrow uptake

    As measured by placing ROI and calculating SUVmax where SUVmax is a mathematical measurement of tumor burden seen on images and calculated by the following equation SUVmax= r / (a'/w) where r= radioactivity concentration in tumor (kBq/ml) as measured by the PET scanner within a defined region of interest, a'=the decay corrected amount of injected 64Cu-LLP2A and w= weight of the patient in grams

    Time frame: Through completion of PET/CT scans (estimated to be up to 2 days)

  3. Evaluate the quality of PET images with new formulation 64Cu-LLP2A as measured by tumor/background ratio

    As measured by placing ROI and calculating SUVmax

    Time frame: Through completion of PET/CT scans (estimated to be up to 2 days)

07

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Aug 2026, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Mar 2027 → Aug 2026 and completion Mar 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Mar 20, 2025
Primary completionActual
Aug 28, 2026was Mar 2027
CompletionActual
Aug 28, 2026was Mar 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Loss of further funding
changed Oct 8, 2026
Primary completion
Mar 31, 2027→Aug 28, 2026 (actual)
Oct 8, 2026
Study completion
Mar 31, 2027→Aug 28, 2026 (actual)
Oct 8, 2026
Enrollment
42 (estimated)→21 (actual)
Oct 8, 2026
Documents
Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Documents Informed consent form ↗ posted
  2. Oct 8, 2026
    Recruiting→Terminated
    Why stopped Loss of further funding
    Primary completion Mar 31, 2027→Aug 28, 2026 (now actual)
    Study completion Mar 31, 2027→Aug 28, 2026 (now actual)
    Enrollment 42 (estimated)→21 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06636175
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Mar 20, 2025
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Oct 16, 2026

Study contacts

Farrokh Dehdashti, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion